相似文献
1
Funding medicines for people with multiple sclerosis.
BMJ. 2001 Dec 15;323(7326):1379-80. doi: 10.1136/bmj.323.7326.1379.
2
Multiple sclerosis drug prompts rationing fears.
BMJ. 1995 Oct 14;311(7011):969. doi: 10.1136/bmj.311.7011.969.
3
Health department to fund interferon beta despite institute's ruling.
BMJ. 2001 Nov 10;323(7321):1087. doi: 10.1136/bmj.323.7321.1087.
4
Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces.
Nurs Stand. 2000;14(44):20. doi: 10.7748/ns.14.44.20.s40.
5
All people with MS have a right to be treated.
Br J Nurs. 2000;9(13):816. doi: 10.12968/bjon.2000.9.13.5506.
6
A cost-utility analysis of interferon beta for multiple sclerosis.
Health Technol Assess. 1998;2(4):iii-54.
7
Trial of interferon-beta in multiple sclerosis stopped early.
Lancet. 1998 Feb 21;351(9102):573. doi: 10.1016/S0140-6736(98)23008-X.
8
The failings of NICE. Doctors treating patients with multiple sclerosis will lose confidence in NICE.
BMJ. 2001 Feb 24;322(7284):491.
9
Drug treatment of multiple sclerosis. Clinical review was unsystematic.
BMJ. 2001 Feb 3;322(7281):299.
10
Funding of drug treatment of multiple sclerosis should not be delayed.
BMJ. 1997 Nov 1;315(7116):1160-1. doi: 10.1136/bmj.315.7116.1160b.
引用本文的文献
1
Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care.
BMJ. 2003 Mar 29;326(7391):707-9. doi: 10.1136/bmj.326.7391.707.
2
Rehabilitation services remain important in multiple sclerosis.
BMJ. 2002 Apr 20;324(7343):977. doi: 10.1136/bmj.324.7343.977.
本文引用的文献
1
Health department to fund interferon beta despite institute's ruling.
BMJ. 2001 Nov 10;323(7321):1087. doi: 10.1136/bmj.323.7321.1087.
2
Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.
Drugs. 2001;61(12):1693-703. doi: 10.2165/00003495-200161120-00001.
Zotero 插件